Navigation Links
PPD Names Daniel Darazsdi as Chief Financial Officer

WILMINGTON, N.C., Sept. 12 /PRNewswire-FirstCall/ -- PPD, Inc. (Nasdaq: PPDI) today announced Daniel G. Darazsdi has been appointed chief financial officer. He will assume his position on October 1.

Mr. Darazsdi, 47, comes to PPD after 25 years with Honeywell International, a $34 billion diversified technology and manufacturing leader, where he most recently served as vice president and CFO of finance transformation and operations. Over the years at Honeywell, he was CFO of the company's global specialty materials business segment and held a variety of leadership roles in finance including business analysis and planning, corporate treasury, financial planning and reporting, and process improvement. In addition, Mr. Darazsdi provided finance, information technology and business development leadership for Honeywell's performance polymers strategic business unit; served in Hong Kong as vice president for the company's Asia- Pacific finance and information technology organizations across 12 countries; and spent several years in Sydney, Australia, directing finance and administration for the company's operations in that country.

"Dan Darazsdi is a seasoned professional whose career portfolio includes extensive experience in business unit finance, corporate treasury and international management," said Fred Eshelman, chief executive officer of PPD. "We are delighted he is joining our organization and look forward to the addition of his strategic leadership to our executive team."

Mr. Darazsdi holds a bachelor of business administration degree from James Madison University, is a graduate of the Honeywell Financial Leadership Development Program and is a certified management accountant.

PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 28 countries and more than 9,700 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions about the above-named employee's performance and value to PPD, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making those forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: the ability to attract and retain key personnel; competition within the outsourcing industry; success in sales growth; economic conditions and outsourcing trends in the pharmaceutical, biotechnology and medical device industries and government-sponsored research sector; loss of or delay in large contracts; dependence on collaborative relationships; rapid technological advances that make our products and services less competitive; risks associated with acquisitions and investments, such as impairments; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.



Louise Caudle

+919 456 4467


Steve Smith

+910 558 7585

Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Wisconsin IT association names Gee president, CEO
2. Quintessence Biosciences names new president
3. CDW names VP to handle Berbee merger
4. NimbleGen names CFO with capital-raising past
5. Cisco names Berbee a top partner of 2005
6. Cisco names Inacom most innovative partner
7. UW-Madison medical school names new dean
8. GE Healthcare names new CEO
9. Bruker AXS names new leadership
10. Sonic Foundry names new senior vice president
11. MyWeather names new president, marketing officer
Post Your Comments:
(Date:10/8/2015)... Fla. , Oct. 8, 2015   Intrexon ... synthetic biology, today announced the appointment of Joseph ... Environment Sector, succeeding Nir Nimrodi who continues ... Vaillancourt will direct Intrexon,s endeavors to generate sustainable, biologically ... America , where he held a variety of ...
(Date:10/8/2015)... IRVINE, Calif. , Oct. 8, 2015 ... announced its expansion into the North American market with ... Asia and Europe ... a pioneer of Target Enrichment methodology and sample preparation ... or NGS, facilitates both hereditary and somatic genetic testing ...
(Date:10/8/2015)... -- The ALS Association, in partnership with Prize4Life, is pleased ... communication technology solutions for people living with ALS. ... lateral sclerosis) is a progressive neurodegenerative disease that affects ... cord. Eventually, people with ALS lose the ability to ... total paralysis and death within two to five years ...
(Date:10/8/2015)... ... 08, 2015 , ... ProMIS Neurosciences, Inc. (TSX: PMN), announced ... commercialize intellectual property rights belonging to The University of British Columbia (UBC). This ... worldwide rights to intellectual property based on use of the ProMIS™ technology, modifications ...
Breaking Biology Technology:
... Sept. 23 S*BIO Pte Ltd today announced ... will support the continued development of S*BIO,s clinical ... reflects the international investment community,s strong interest in ... clinical development and the quality of our various ...
... China, Sept. 22 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, ... ), which develops, manufactures, and markets specialty pharmaceutical ... has successfully completed Phase I clinical trials of ... Cephalosporin continues to be the most widely prescribed ...
... VANCOUVER, Sept. 22 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ... of results from a randomized Phase 2 trial ... results showed a survival benefit with the investigational ... cancer. The median overall survival for patients who ...
Cached Biology Technology:
(Date:10/6/2015)... Oct. 6, 2015  Maverix Biomics, Inc., a ... to its software portfolio with the debut of ... differential expression in eukaryotes. The software is integrated ... cloud-based genomic analysis solution that leverages proven open-source ... next-generation sequencing efforts. Garry Nolan,s ...
(Date:9/30/2015)... , Sept. 30, 2015  With nearly 300,000 Americans ... of new SCIs estimated to reach 12,500 annually, the ... California Resource Services for Independent Living (SCRS-IL) is ... California opening doors to independence ... programs and services, notably assistive technology services and education. ...
(Date:9/29/2015)... is excited to be named one of the first 100 ... announcement was recently made at an invite-only IBM Watson: ... Francisco , where iDAvatars presented a demo of its ... "It is both an honor and a privilege to be ... the cognitive power of IBM Watson in our product, which ...
Breaking Biology News(10 mins):
... RIVERSIDE, Calif. With the Easter holiday season coming up ... hens in egg farms producing the maximum number of eggs they ... can reduce egg production by five percent or more," says ... the University of California, Riverside. "One way to boost egg ...
... 2011 Stanford University professor Axel T. Brunger has ... Biochemistry and Molecular Biology,s inaugural DeLano Award for Computational ... Structural Biology with Single Molecules" at 9:03 a.m. on ... at the Walter E. Washington Convention Center in Washington, ...
... Mass. A single change to even one of the ... the human genome can result in severe diseases such as ... minor change in the DNA of a virus or bacteria ... for physicians to treat with standard drug therapies. For these ...
Cached Biology News:
Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
Synaptotagmin, phosphoSer309...
... anti-phospho-PTEN (Ser385) ... amino acid region encompassing the ... (Ser385), Accession ... Quality Assurance: Routinely ...
Allophycocyanin (APC) anti-human CD193 (CCR3, CKR3) 25 tests...
Biology Products: